Abstract：
It remains unclear how effective COVID-19 vaccinations will be in patients with weakened immunity due to diseases, transplantation, and dialysis. We conducted a systematic review comparing the efficacy of COVID-19 vaccination in patients with solid tumor, hematologic malignancy, autoimmune disease, inflammatory bowel disease, and patients who received transplantation or dialysis. A literature search was conducted twice using the Medline/PubMed database. As a result, 21 papers were included in the review, and seropositivity rate was summarized by specific type of disease, transplantation, and dialysis. When different papers studied the same type of patient group, a study with a higher number of participants was selected. Most of the solid tumor patients showed a seropositivity rate of more than 80% after the second inoculation, but a low seropositivity was found in certain tumors such as breast cancer. Research in patients with certain types of hematological malignancy and autoimmune diseases has also reported low seropositivity, and this may have been affected by the immunosuppressive treatment these patients receive. Research in patients receiving dialysis or transplantation has reported lower seropositivity rates than the general population, while all patients with inflammatory bowel disease have converted to be seropositive. Meta-analysis validating these results will be needed, and studies will also be needed on methods to protect patients with reduced immunity from COVID-19.
摘要：
目前尚不清楚COVID-19疫苗在因疾病而免疫力下降的患者中的效果如何，移植,和透析。我们进行了一项系统评价，比较了COVID-19疫苗在实体瘤患者中的疗效，恶性血液病,自身免疫性疾病，炎症性肠病，以及接受移植或透析的患者。使用Medline/PubMed数据库进行两次文献检索。因此,21篇论文被纳入审查，血清阳性率按特定疾病类型进行总结，移植,和透析。当不同的论文研究相同类型的患者组时，我们选择了一项参与者数量较多的研究.大多数实体瘤患者在第二次接种后血清阳性率超过80%，但是在某些肿瘤如乳腺癌中发现了低血清阳性。对某些类型的血液系统恶性肿瘤和自身免疫性疾病患者的研究也报道了低血清阳性，这可能受到这些患者接受的免疫抑制治疗的影响。接受透析或移植的患者的研究报告血清阳性率低于一般人群，而所有炎症性肠病患者均转为血清阳性。将需要验证这些结果的荟萃分析，还需要研究保护免疫力下降的患者免受COVID-19感染的方法。
